This is a published notice on the Find a Tender service: https://www.find-tender.service.gov.uk/Notice/006306-2021

Tender

IMPACTT PROJECT- The Supply and Delivery of COVID-19 Samples

Medicines Discovery Catapult

F02: Contract notice

Notice identifier: 2021/S 000-006306

Procurement identifier (OCID): ocds-h6vhtk-02a014

Published 27 March 2021, 4:25pm

Section I: Contracting authority

I.1) Name and addresses

Medicines Discovery Catapult

Block 35, Mereside, Alderley Park

Cheshire

SK10 4TG

Contact

Ms Laura Hough

Email

laura.hough@md.catapult.org.uk

Telephone

+44 1625708394

Country

United Kingdom

NUTS code

UK - United Kingdom

Internet address(es)

Main address

https://md.catapult.org.uk/

Buyer's address

https://md.catapult.org.uk/

I.2) Information about joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

https://procontract.due-north.com/Advert/Index?advertId=955b7df5-158f-eb11-810c-005056b64545

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

https://procontract.due-north.com/Advert/Index?advertId=955b7df5-158f-eb11-810c-005056b64545

I.4) Type of the contracting authority

Other type

Research - Drug Discovery

I.5) Main activity

Other activity

Research - Drug Discovery

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

IMPACTT PROJECT- The Supply and Delivery of COVID-19 Samples

Reference number

DN535169

II.1.2) Main CPV code

• 33000000 - Medical equipments, pharmaceuticals and personal care products

II.1.3) Type of contract

Supplies

II.1.4) Short description

This Invitation to Tender (ITT) has been issued by MDC for the establishment of a Framework Agreement for IMPACTT PROJECT- The Supply and Delivery of COVID-19 Samples for delivery to Oncimmune.

II.1.5) Estimated total value

Value excluding VAT: £1,100,000

II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

II.2) Description

II.2.1) Title

Lot 1 Discovery

Lot No

1

II.2.2) Additional CPV code(s)

• 33000000 - Medical equipments, pharmaceuticals and personal care products

II.2.3) Place of performance

NUTS codes

• UK - United Kingdom

II.2.4) Description of the procurement

We are looking for appropriate tender responses for the provision of SARS-COV-2 patient samples in order to appoint suppliers onto a Framework Agreement, with the aim of providing clinical samples for immune profiling. The IMPACTT project started 01/10/2020 therefore the SARS-COV-2 samples are required as soon as possible and there is a preference for banked samples which is detailed within the call off criteria section 12 of the ITT. The first set SAR-COV-2 samples are required as soon as possible, no later than 30th June 2021 (unless otherwise agreed by MDC / Oncimmune) to ensure project delivery. Sample requirements are outlined in figure 1 Sample characteristics distribution model within this document. It is anticipated that a maximum of ten (10) suppliers for each lot will be appointed to the framework agreement; however, MDC reserves the right to appoint fewer or more than this number if it is deemed to be in MDC's best interest.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £550,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 2 Validation

Lot No

2

II.2.2) Additional CPV code(s)

• 33000000 - Medical equipments, pharmaceuticals and personal care products

II.2.3) Place of performance

NUTS codes

• UK - United Kingdom

II.2.4) Description of the procurement

We are looking for appropriate tender responses for the provision of SARS-COV-2 patient samples in order to appoint suppliers onto a Framework Agreement, with the aim of providing clinical samples for immune profiling. The IMPACTT project started 01/10/2020 therefore the SARS-COV-2 samples are required as soon as possible and there is a

preference for banked samples which is detailed within the call off criteria section 12 of the ITT. The first set SAR-COV-2 samples are required as soon as possible, no later than 30th June 2021 (unless otherwise agreed by MDC / Oncimmune) to ensure project delivery. Sample requirements are outlined in figure 1 Sample characteristics distribution model within this document. It is anticipated that a maximum of ten (10) suppliers for each lot will be appointed to the framework agreement; however, MDC reserves the right to appoint fewer or more than this number if it is deemed to be in MDC's best interest.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £550,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

36

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

Accelerated procedure

Justification:

The Tender is being conducted under the Accelerated Procedure. MDC has determined that a state of urgency exists that renders impracticable the time limit laid down in the PCR. Therefore, the time limit shall be not less than 15 calendar days from the date on which the contract notice is sent. The rationale for this is that MDC have previously advertised within OJEU the tender for The Supply and Delivery of COVID-19 Samples, however unfortunately no suitable bids were submitted. Due to this MDC have reviewed their specification and are now reissuing the tender based on the requirements laid down in the Specification Appendix 3. The Covid-19 Samples are required for an Innovate UK funded project studying the immune profiled of 3000 patients infected with SARS-CoV-2. The project started 01/10/2020 and the samples are required by 30/06/2021 (or a date agreed by MDC / Oncimmune and the awarded Supplier). MDC do not have the time to undertake a full open procedure tendering exercise.

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

In the case of framework agreements, provide justification for any duration exceeding 4 years:

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

\neg		
1)	Э.	ГΔ

15 April 2021

Local time

12:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 12 (from the date stated for receipt of tender)

IV.2.7) Conditions for opening of tenders

Date

15 April 2021

Local time

12:00pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.4) Procedures for review

VI.4.1) Review body

Medicines Discovery Catapult

Block 35, Mereside, Alderley Park

Macclesfield

SK10 4TG

Country

United Kingdom